Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas

2014/09/22 by Jinhua Wang, Sharon K. Huang, Diego M. Marzese +13 · 26 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Melanoma and MAPK Pathways #Cutaneous Melanoma Detection and Management #Histone Deacetylase Inhibitors Research

paper · pdf · doi:10.1038/jid.2014.418

Citations

• Cancer statistics, 2012

Cited by

• Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping
• A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. [europepmc]
• Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. [europepmc]
• Patterns of gene expression and DNA methylation in human fetal and adult liver. [europepmc]
• Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools. [europepmc]
• FOXC1 promotes melanoma by activating MST1R/PI3K/AKT. [europepmc]
• Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma. [europepmc]
• Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. [europepmc]
• Epigenetic regulation of RTK signaling. [europepmc]
• Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. [europepmc]
• miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. [europepmc]
• Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies. [europepmc]
• 3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase. [europepmc]
• Neuropilins in the Context of Tumor Vasculature. [europepmc]
• Polytherapy and Targeted Cancer Drug Resistance. [europepmc]
• Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression. [europepmc]
• Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity. [europepmc]
• Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. [europepmc]
• Current Advances in the Treatment of BRAF-Mutant Melanoma. [europepmc]
• Targeted Therapy in Melanoma and Mechanisms of Resistance. [europepmc]
• Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. [europepmc]
• In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors. [europepmc]
• Mechanisms of Functional Pleiotropy of p73 in Cancer and Beyond. [europepmc]
• Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges. [europepmc]
• BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. [europepmc]
• BRAF - a tumour-agnostic drug target with lineage-specific dependencies. [europepmc]